A simple sore throat can sometimes trigger years of silent heart damage. Rheumatic heart disease grows quietly, often ...

UniQure stock dropped after the FDA sent feedback on the company's pending treatment for Huntington's disease. Read more on ...

Peake relates the story of folk music legend Woody Guthrie, “our greatest advocate,” if only by accident. The ...

Neurocrine Biosciences (NBIX) may be undervalued, with strong Ingrezza growth, Crenessity's billion-dollar potential, and a ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their ...

Published, peer-reviewed narrative review in CNS Spectrums compiles pharmacologic, pharmacokinetic and clinical data of VMAT2 inhibitors to highlight ...

Despite challenges like high therapy costs and regulatory hurdles, continuous R&D investments and strategic collaborations are fostering progress in personalized medicine, addressing critical unmet ...

Net (Loss) Income: The net loss attributable to Serina for the three months ended September 30, 2025 was $4.6 million, or $0.45 per basic and diluted share, compared to net income of $1.4 million, or ...

Teva stock rocketed into a profit-taking zone Wednesday after the company put up a big sales beat for its drug Austedo in the U.S.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major ...

Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New ...

SOM3355 is still an investigational drug, and only a Phase 3 trial can determine whether it is safe and effective enough to seek approval. But the combined momentum from the EMA and FDA reflects a ...